T. Alfaro (Coimbra, Portugal), N. Chaudhuri (Manchester (Greater Manchester), United Kingdom)
Yoga in patients with fibrosing interstitial lung diseases – a feasibility trial
M. Kreuter (Heidelberg, Germany), L. Wasmuth (Heidelberg, Germany), M. Kotzerke (Heidelberg, Germany), S. Hummler (Heidelberg, Germany), R. Koczulla (Marburg, Germany), N. Stenzel (berlin, Germany), C. Ganter (Heidelberg, Germany)
|   |
Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis?
S. Satar (Ankara, Turkey), I. Candemir (Ankara, Turkey), P. Ergun (Ankara, Turkey), H. Karamanli (Ankara, Turkey)
| |
Feasibility of a cardiopulmonary exercise test (CPET) derived high-intensity interval training programme (HIIT) in idiopathic pulmonary fibrosis (IPF)
T. Wallis (Southampton, United Kingdom), K. Pontoppidan (Southampton, United Kingdom), K. Gove (Southampton, United Kingdom), D. Hill (Southampton, United Kingdom), J. Cullinane (Southampton, United Kingdom), F. Thompson (Southampton, United Kingdom), C. Brereton (Southampton, United Kingdom), A. Freeman (Southampton, United Kingdom), S. Fletcher (Southampton, United Kingdom), M. Grocott (Southampton, United Kingdom), M. Jones (Southampton, United Kingdom), S. Jack (Southampton, United Kingdom)
| |
Measuring patient activation in an interstitial lung disease (ILD) population: an exploratory study
A. Russell (LondonLondonLondoLondollllondonLondonlolnnLondon, United Kingdom), R. Aul (London, United Kingdom), A. Datta (London, United Kingdom), M. Wickremasinghe (London, United Kingdom)
| |
Association between influenza vaccination and the occurrence of acute exacerbation in idiopathic pulmonary fibrosis
L. Sese (Bobigny, France), J. Caliez (Bobigny, France), V. Cottin (Lyon, France), D. Israel-Biet (Paris, France), B. Crestani (Paris, France), S. Guillot-Dudoret (Rennes, France), J. Cadranel (Paris, France), B. Wallaert (Lille, France), A. Tazi (Paris, France), B. Maître (Créteil, France), G. Prévot (Toulouse, France), S. Marchan-Adam (Tours, France), S. Hirschi (Strasbourg, France), S. Dury (Reims, France), V. Giraud (Boulogne, France), A. Gondouin (Besançon, France), P. Bonniaud (Dijon, France), J. Traclet (Lyon, France), K. Juvin (Paris, France), R. Borie (Paris, France), T. Gille (Bobigny, France), Z. Carton (Bobigny, France), D. Valeyre (Bobigny, France), H. Nunes (Bobigny, France)
| |
Outcomes at Week 12 from three RCTs of sildenafil with and without antifibrotics in advanced IPF
J. Behr (Munich, Germany), S. Nathan (Falls Church, VA, United States of America), S. Harari (Milan, Italy), W. Wuyts (Leuven, Belgium), K. Kirchgaessler (Basel, Switzerland), M. Bengus (Basel, Switzerland), F. Gilberg (Basel, Switzerland), A. Wells (London, United Kingdom)
| |
Treatment efficacy of idiopathic pulmonary fibrosis depending on the dose difference of pirfenidone
Y. Shin (Seoul, Republic of Korea), C. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), H. Yoon (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea), J. Park (Seoul, Republic of Korea), Y. Lee (Seoul, Republic of Korea), S. Lim (Seoul, Republic of Korea), Y. Lee (Seoul, Republic of Korea), S. Choi (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea)
| |
Pirfenidone side-effect risk stratification: targeting nursing support at a single UK prescribing centre
C. Ruggiero (Oxford, United Kingdom), S. Poole (Oxford, United Kingdom), R. Hoyles (Oxford, United Kingdom)
| |
INTEGRIS-IPF: a 12-week, Phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF
E. Lefebvre (South San Francisco, United States of America), B. Coulie (South San Francisco, United States of America), M. Jurek (South San Francisco, United States of America), J. Bellini (South San Francisco, United States of America), F. Cilli (South San Francisco, United States of America), S. Wong (South San Francisco, United States of America), M. Decaris (South San Francisco, United States of America), S. Turner (South San Francisco, United States of America), E. Park (South San Francisco, United States of America)
| |
Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
F. Mccormack (Cincinnati, United States of America), M. Yang (South San Francisco, United States of America), E. Morgenthien (South San Francisco, United States of America), C. Burg (South San Francisco, United States of America), J. Axmann (Basel, Switzerland), J. Stauffer (South San Francisco, United States of America)
| |
Idiopathic pulmonary fibrosis (IPF): observations from a Phase 2 trial of GLPG1205 (PINTA)
I. Strambu (Bucharest, Romania), L. Fagard (Mechelen, Belgium), P. Ford (Mechelen, Belgium), T. Van Der Aa (Mechelen, Belgium), A. De Haas-Amatsaleh (Mechelen, Belgium), E. Santermans (Mechelen, Belgium), C. Seemayer (Mechelen, Belgium)
| |
Computed Tomography Findings as Determinants of Pulmonary Function Tests in Fibrotic Interstitial Lung Diseases
D. Lang (Linz, Austria), K. Akbari (Linz, Austria), A. Horner (Linz, Austria), M. Hepp (Linz, Austria), B. Kaiser (Linz, Austria), H. Pieringer (Linz, Austria), M. Studnicka (Salzburg, Austria), B. Lamprecht (Linz, Austria)
| |
Evolution of the ‘Indeterminate UIP’ HRCT pattern; a cohort snapshot
A. Achaiah (Oxford, United Kingdom), A. Pereira (Oxford, United Kingdom), H. Bothwell (Oxford, United Kingdom), A. Rathnapala (Oxford, United Kingdom), K. Dwivedi (Oxford, United Kingdom), R. Barker (Oxford, United Kingdom), R. Hoyles (Oxford, United Kingdom), L. Ho (Oxford, United Kingdom)
| |
Single-arm observational study of a mobile app + home spirometry in idiopathic pulmonary fibrosis
L. Fox (Dublin, Ireland), L. Mcleod (Dublin, Ireland), A. Russell (London, United Kingdom), C. Edwards (Dublin, Ireland), K. O'Reilly (Dublin, Ireland)
| |
eHealth in pulmonary fibrosis: an international survey among healthcare providers and patients
G. Nakshbandi (Rotterdam (ZH), Netherlands), C. Moor (Rotterdam (ZH), Netherlands), J. Aerts (Rotterdam (ZH), Netherlands), M. Wijsenbeek (Rotterdam (ZH), Netherlands)
| |
Diagnostic value of cryobiopsy in patients with interstitial lung diseases integrating bronchoalveolar lavage, radiologic and clinical data
K. Hostettler (Basel, Switzerland), S. Savic (Basel, Switzerland), L. Bubendorf (Basel, Switzerland), P. Grendelmeier (Basel, Switzerland), K. Jahn (Basel, Switzerland), D. Stolz (Basel, Switzerland), J. Bremerich (Basel, Switzerland), M. Tamm (Basel, Switzerland)
| |
Concurrent validity among three field tests and the cardiopulmonary exercise testing in patients with idiopathic pulmonary fibrosis.
D. Dos Reis Estrella (Belo Horizonte (MG), Brazil), H. Pereira (Belo Horizonte (MG), Brazil), E. Viana Mancuzo (Belo Horizonte (MG), Brazil), G. Samora (Belo Horizonte (MG), Brazil), B. Silveira (Belo Horizonte (MG), Brazil), A. Pataro (Belo Horizonte (MG), Brazil), V. Parreira (Belo Horizonte (MG), Brazil)
| |